1. Home
  2. Approved trials
  3. » فارسی

Efficacy of Verapamil in patients with chronic rhinosinositis with nasal polyposis reffered to Hazrat Rasool hospital: Double blind placebo control trial

Protocol summary

Study aim
Potential morbidity of steroids in chronic rhinosinusitis with nasal polyposis (CRSwNP) treatment induces researches to alternative treatments with the same clinical efficacy but with at least side effects that is needed enough information about CRSwNP pathophysiology , diagnostic biomarkers and targeted therapies. P - gp is a new biomarker and plays an important role in CRSwNP pathogenesis. P- gp suppression is a new strateghy in treatment of disease. Verapamil is P- gp suppressor and suppresses P- gp in sinonasal epithelial cells. Low doses Verapamil are tolerated by healthy patients with cluster headache, that will be prescribed in addition to routin treatment for 3 months. Results of research will be measured based on subjective and objective findings. Different studies have shown Verapamil efficacy in CRSwNP treatment with no side effects. The goal of this research is confirming efficacy, safety and novelty of Verapamil in CRSwNP treatment.
Design
Randomized, double blind, placebo contol trial in 2 equal groups with 18 ones for 3 months
Settings and conduct
Low doses are tolerated by healthy patients with cluster headache. Oral Verapamil (80 mg, 3 times a day) and placebo has the same characteristics.Randomization is based on Random allocation software. Primary outcome measure is SNOT-22 questionnaire. Secondary outcome measure is (Lund- McKey score) LMS. Evaluations are done in beginning and after 12 weeks.
Participants/Inclusion and exclusion criteria
Patients referred to hospital with CRSwNP between 18-55. Patients with certain comorbidities, drugs and conductive heart disease HR<60 or SBP<110 or DBP<70
Intervention groups
groups receiving Verapamil and placebo
Main outcome variables
Age, Sex, BMI, Prior sinus surgery, concommitant Asthm, NSAID allergy, smoking, SNOT-22 score, serum total IgE, Eosinophilia in blood and nasal secretions, Odor level, LMS score

General information

Reason for update
Acronym
CRSwNP
IRCT registration information
IRCT registration number: IRCT20191014045107N1
Registration date: 2019-12-09, 1398/09/18
Registration timing: registered_while_recruiting

Last update: 2019-12-09, 1398/09/18
Update count: 0
Registration date
2019-12-09, 1398/09/18
Registrant information
Name
Afshin Rezaeifar
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 21 6655 4933
Email address
rezaeifar.a@iums.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2019-10-23, 1398/08/01
Expected recruitment end date
2020-01-21, 1398/11/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Efficacy of Verapamil in patients with chronic rhinosinositis with nasal polyposis reffered to Hazrat Rasool hospital: Double blind placebo control trial
Public title
Efficacy of Verapamil in patients with chronic rhinosinositis with nasal polyposis
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Patients of Male And Female reffered to Allergy and Clinical Immunology Department of Hazrat e Rasool Center Age between 18-55 years old Diagnosed with Chronic Rhinosinusitis with Nasal Polyps according to the EPOS 2012 consensus criteria; Moderate to Severe (Baseline SNOT-22 Score ≥20)
Exclusion criteria:
Patients with the following comorbidities: GI Hypomotility, Heart Failure, Liver Failure, Kidney Disease, Muscular Dystrophy, Pregnant or Nursing Females, Hypertrophic Cardiomyopathy, Atrial and ventricular arrhythmia Patients with conductive heart disease like block grade 2 or 3 in EKG Patients taking the following medications; Aspirin, Beta-blockers, Cimetidine, Clarithromycin, Erythromycin, Cyclosporin, Digoxin, Disopyramide, Diuretics, Flecainide, HIV Protease Inhibitors(Indinavir, Nelfinavir, Ritonavir), Quinidine, Lithium, Pioglitazone, Rifampin and systemic corticosteroids one month before trial HR<60 or SBP<110 or DBP<70
Age
From 18 years old to 55 years old
Gender
Both
Phase
2-3
Groups that have been masked
  • Participant
  • Care provider
  • Investigator
  • Outcome assessor
Sample size
Target sample size: 36
More than 1 sample in each individual
Number of samples in each individual: 18
18 ones in Verapamil group and 18 ones in Placebo control group
Randomization (investigator's opinion)
Randomized
Randomization description
Randomization is based on ZIP code and Random allocation software
Blinding (investigator's opinion)
Double blinded
Blinding description
Patients randomly are divided two equal double blind groups that receiving verapamil, INS, irrigation or irrigation, INS, Placebo .This study is randomized double placebo control trial and the third person gives Drug and Placebo to patients equally.
Placebo
Used
Assignment
Single
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of IRAN University of Medical Sciences
Street address
Hazrat E Rasool Hospital, Niayesh Ave., Sattarkhan Ave., Tehran
City
Tehran
Province
Tehran
Postal code
1449614535
Approval date
2019-10-09, 1398/07/17
Ethics committee reference number
IR.IUMS.FMD.REC.1398.291

Health conditions studied

1

Description of health condition studied
Chronic Rhinosinusitis With polyoposis, Verapamil
ICD-10 code
ICD-10 code description

Primary outcomes

1

Description
Efficacy of Verapamil in treatment of patients with CRSwNP based on SNOT-22 questionnaire score
Timepoint
SNOT-22 questionnaire completion in beginning and after 12 weeks of study
Method of measurement
SNOT-22 questionnaire validated in Farsi

Secondary outcomes

1

Description
Efficacy of Verapamil in treatment of CRSwNP based on Lund - Mc Key score in sinonasal computer tomography scan
Timepoint
Measurement of LMS score in beginning and after 12 weeks of study
Method of measurement
Lund - Mc Key score in sinonasal computer tomography scan by 2 unrelated specialist

Intervention groups

1

Description
Intervention group: Receiving Verapamil Patients randomly are divided in 18 equal double - blind placebo control in 2 groups . Group 1 receive Verapamil plus Intranasal mometasone plus Nasal irrigation and Group 2 receive Placebo plus Intranasal mometasone plus Nasal irrigation. Minimum dose Verapamil use based on safety dose in Cluster headache that is defined Tab Verapamil 80 mg TDS . This study will do for 3 months. Placebo has the same characteristic of Tab Verapamil (Size, Color, Teste). Drug and Placebo are produced in Alborz daroo pharmaceutical company. FDA approved Intranasal corticosteroid is mometasone. Randomization is based on ZIP code and Random allocation software.
Category
Treatment - Drugs

2

Description
control group: Receiving Placebo Patients randomly are divided in 18 equal double - blind placebo control in 2 groups . Group 1 receive Verapamil plus Intranasal mometasone plus Nasal irrigation and Group 2 receive Placebo plus Intranasal mometasone plus Nasal irrigation. Minimum dose Verapamil use based on safety dose in Cluster headache that is defined Tab Verapamil 80 mg TDS . This study will do for 3 months. Placebo has the same characteristic of Tab Verapamil (Size, Color, Teste). Drug and Placebo are produced in Alborz daroo pharmaceutical company. FDA approved Intranasal corticosteroid is mometasone. Randomization is based on ZIP code and Random allocation software.number and Random allocation software.
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Hazrat E Rasool hospital
Full name of responsible person
Mohammad Nabavi
Street address
Hazrat e Rasool hospital, Niayesh Ave., Sattarkhan Ave., Tehran
City
Tehran
Province
Tehran
Postal code
1445613131
Phone
+98 21 6655 4933
Fax
+98 21 6655 4933
Email
mnabavi44@yahoo.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Iran University of Medical Sciences
Full name of responsible person
Seied Abbas Motavalian
Street address
Iran medical university, Hemat Boul., Tehran
City
Tehran
Province
Tehran
Postal code
1449614535
Phone
+98 21 86701
Email
adminsite@iums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Iran University of Medical Sciences
Proportion provided by this source
1
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Iran University of Medical Sciences
Full name of responsible person
Mohammad Nabavi
Position
Associate professor
Latest degree
Subspecialist
Other areas of specialty/work
Others
Street address
Hazrat e Rasool hospital, Niayesh Ave., Sattarkhan Ave., Tehran
City
Tehran
Province
Tehran
Postal code
1445613131
Phone
+98 21 6655 4933
Email
mnabavi44@yahoo.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Iran University of Medical Sciences
Full name of responsible person
Afshin Rezaeifar
Position
Subspecialty Resident
Latest degree
Specialist
Other areas of specialty/work
Others
Street address
Hazrat e Rasool hospital, Niayesh Ave., Sattarkhan Ave., Tehran
City
Tehran
Province
Tehran
Postal code
1445613131
Phone
+98 21 6655 4933
Fax
+98 21 6655 4933
Email
afshinrezaeifar@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Iran University of Medical Sciences
Full name of responsible person
Afshin Rezaeifar
Position
Subspecialty Resident
Latest degree
Specialist
Other areas of specialty/work
Others
Street address
Hazrat e Rasool hospital, Niayesh Ave., Sattarkhan Ave., Tehran
City
Tehran
Province
Tehran
Postal code
1445613131
Phone
+98 21 6655 4933
Fax
+98 21 6655 4933
Email
Afshinrezaeifar@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Yes - There is a plan to make this available
Data Dictionary
Yes - There is a plan to make this available
Title and more details about the data/document
All data is acceptable after unidentifying people.
When the data will become available and for how long
Beginning period of acceptance is 6 months after printing of results.
To whom data/document is available
Data is acceptable only researchers who are working in academic and scientific centers
Under which criteria data/document could be used
Use of data is allowed for research applications.
From where data/document is obtainable
Receiving of documents will done by E-mail address.
What processes are involved for a request to access data/document
Receiving of documents will done by E-mail address in one month.
Comments
Loading...